FLAG 094
Alternative Names: FLAG-094Latest Information Update: 26 Apr 2021
At a glance
- Originator Duquesne University
- Developer FLAG Therapeutics
- Class Amines; Antineoplastics; Glutamates; Pyrimidines; Pyrroles; Small molecules; Thiophenes
- Mechanism of Action Phosphoribosylglycinamide formyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mesothelioma
Most Recent Events
- 26 Apr 2021 FLAG Therapeutics has multiple patents pending for purine synthesis inhibitors (FLAG Therapeutics pipeline, April 2021)
- 26 Apr 2021 FLAG Therapeutics has multiple patents granted for purine synthesis inhibitors (FLAG Therapeutics pipeline, April 2021)
- 30 Mar 2021 Preclinical trials in Mesothelioma in USA (unspecified route) before March 2021 (FLAG Therapeutics pipeline, March 2021)